Company Description

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong.

It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.

The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Regencell Bioscience Holdings Limited

Country	Hong Kong
Founded	2014
IPO Date	Jul 16, 2021
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	10
CEO	Yat-Gai Au

Contact Details

Address: Chinachem Leighton Plaza, 9th Floor Causeway Bay Hong Kong
Phone	852 2155 0823
Website	regencellbioscience.com

Stock Details

Ticker Symbol	RGC
Exchange	NASDAQ
Fiscal Year	July - June
Reporting Currency	USD
IPO Price	$9.50
CIK Code	1829667
CUSIP Number	G7487R100
ISIN Number	KYG7487R1002
SIC Code	2833

Key Executives

Name	Position
Yat-Gai Au	Founder, Chairman and Chief Executive Officer
Michelle Chan	Financial Controller, Chief Financial Officer and Principal Financial Officer
Wai Hong Chung	Chief Operating Officer, Chief Strategy Officer and Director
Antonia Assang	Senior Vice President of Project Management
Yat-Pui Au	Chief Business Officer

Latest SEC Filings

Date	Type	Title
May 22, 2026	6-K	Report of foreign issuer
May 19, 2026	424B5	Filing
May 19, 2026	6-K	Report of foreign issuer
May 19, 2026	6-K	Report of foreign issuer
May 8, 2026	6-K	Report of foreign issuer
Apr 17, 2026	6-K	Report of foreign issuer
Mar 30, 2026	6-K	Report of foreign issuer
Mar 30, 2026	6-K	Report of foreign issuer
Mar 30, 2026	424B5	Filing
Mar 30, 2026	F-3ASR	Filing

View All SEC Filings